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Abstract
Background Orodispersible tablets (ODTs) are tablet or
wafer forms of medication that disintegrate in the mouth,
aided only by saliva. ODTs rely on different fast dissolve/
disintegration manufacturing technologies.
Objectives Disintegration time differences for several
olanzapine ODT forms were investigated. Risperdal
M-Tab was included as a non-olanzapine ODT
comparator.
Research Design and Methods Eleven olanzapine ODT
examples and orodispersible risperidone strengths were
evaluated in vitro for formulation composition, manufac-
turing method, disintegration and dissolution characteristics,
and formulation differences in comparison with freeze dried
Zydis ODT. Automated dissolution test equipment cap-
tured ODT dissolution rates by measuring real-time release
of active ingredient. A high-speed video camera was used to
capture tablet disintegration times in warm simulated saliva.
Main Outcome Measure The main outcome measure was
the disintegration and dissolution characteristics of the
ODT formulations.
Results The ODT manufacturing method was associated
with time to disintegrate; the fastest were freeze dried tablets,
followed by soft compressed tablets and then hard/dense
tablets. Olanzapine Zydis was the only ODT that com-
pletely disintegrated in less than 4 s for all strengths (5, 10,
15, and 20 mg), followed by 5-mg Prolanz FAST (12 s) and
then risperidone ODT 4 mg (40 s). Reasons for slow disso-
lution of the olanzapine generics may include low product
potency, excipient binding, excipient solubility, active
ingredient particle size and incomplete disintegration.
Conclusions Differences in the formulation and manu-
facturing process of olanzapine ODTs appear to have a
strong influence on the disintegration time of the active
compound; differences that may potentially impact their use
in clinical practice.
1 Introduction
The treatment of mental disorders usually requires pro-
longed pharmacotherapy in order to resolve the current
episode and reduce the risk for recurrence of symptoms,
while addressing the challenges of low compliance in the
long term. Such prolonged therapy requires considerable
commitment on the part of patients to take their medication
as prescribed. Medication compliance is often challenging
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among psychiatric patients, including those with schizo-
phrenia or bipolar disorder; this can be associated with
poor long-term outcomes and, ultimately, treatment failure
[1].
A greater understanding of patients’ preferences for new
formulations of treatment is central to current models of
shared patient–doctor decision making, and has gained
considerable interest in scientific research for orodispers-
ible formulations of antidepressants and antipsychotics [2].
The effectiveness of the antipsychotic drug olanzapine
classic oral tablet in the treatment of patients with
schizophrenia has been widely investigated in several
randomized, controlled trials, and observational studies [3–
7] and in several meta-analyses [8, 9].
In recent years, more clinical attention has been paid to
oral dispersible tablet formulation of medications [10].
Lyophilized (freeze dried), orally disintegrating olanzapine
is a rapid dissolving formulation of olanzapine that disin-
tegrates in saliva almost instantaneously. The formulation
was developed as a convenient, easy to ingest and poten-
tially adherence-enhancing alternative to the standard
olanzapine coated tablet. Pharmacokinetic studies have
shown that the olanzapine orodispersible tablet (ODT) is
bioequivalent to olanzapine standard tablet with the same
rate and extent of bioavailability [11]. Clinical studies have
shown that olanzapine ODTs and standard olanzapine
tablets have similar efficacy and tolerability profiles;
however, olanzapine ODTs appear to have a number of
advantages over olanzapine standard tablets in terms of
adherence, patient preference and reduction in nursing
burden [2, 12, 13].
Olanzapine ODTs may be useful for patients who have
difficulty swallowing standard tablets; those with poor
insight who may try to cheek or spit out their medication;
those who need to have their ingestion verified but who do
not want an injection; or those who prefer this formulation
for other reasons. There are many generic olanzapine
orodispersible formulations, but their relative disintegra-
tion and dispersion times have never been studied to our
knowledge. Variation in dispersion times might be expec-
ted, depending on the different fast dissolve/disintegration
technologies used to manufacture the tablets and/or the
disintegration test used to evaluate them. Olanzapine Zy-
dis (also known as Velotab) is manufactured by Catalent
Pharma Solutions (Somerset, NJ, USA), and is made by a
freeze drying process that provides a low-density, highly
porous structure that readily disintegrates in the oral cavity.
Although bioequivalence is accepted for generic ODTs, the
time it takes for an ODT to disintegrate and dissolve in the
oral cavity may potentially impact clinical parameters such
as patient acceptance and adherence to treatment.
For olanzapine Zydis ODT, the elapsed time for initial
and complete disintegration was measured in two small
in vivo studies [14, 15]. However, these studies used dif-
ferent methods: one took the first measurement of initial
disintegration at 15 s, while the other took the first mea-
surement at 5 s. It is desirable to compare disintegration
times among different products using the same methodol-
ogy. Given the obvious challenges of standardizing in vivo
assessments, the objective of our current in vitro compar-
ison was to investigate in vitro disintegration time and
dissolution rate differences of various generic formulations
of olanzapine ODT relative to olanzapine Zydis in sim-
ulated saliva. We also compared the chemical and physical
properties of each ODT and measured in vitro disintegra-
tion time for risperidone ODT [16] as a comparator.
2 Materials and Methods
All types of olanzapine ODT that could be obtained were
evaluated (Table 1). Eleven different examples were filmed
to determine disintegration times, and all were evaluated
for manufacturing method, dissolution characteristics and
formulation differences, including the freeze dried Zydis
formulation of olanzapine ODT and risperidone ODT.
A Canon XHL1 HD camera (Canon, Tokyo, Japan) was
used to capture a 3-min disintegration event for each ODT
product added to 30 mL of non-agitated 37 C (initial
temperature) simulated saliva solution in a 10-cm Petri
dish. Disintegration was defined as the time it took a tablet
to reach full dispersion after addition to the artificial saliva
(see Table 2 for the formulation, based on formulations
described in Giannola et al. [17] and Gal et al. [18]). Drug
product excipient data were obtained from published
product literature. Dose form and manufacturing method
(compressed tablet, lyophilized wafer) were determined by
microscopic/visual observation.
Dissolution testing used a USP Apparatus #2, DISTEK
DISBA0045 and DISBA0046 with an Opt-Diss UV fiber
optic SPEC0088 attachment (Distek Inc., North Bruns-
wick, NJ, USA). The system quantified the solubilized
antipsychotic in 500 mL of 37 C simulated saliva every
10 s for 6 min, and then every minute for 14 min, with
paddle speeds of 20 or 30 rpm to simulate the oral cavity
environment [16] (Table 3). Agitation was then increased
150 rpm for an additional 16 min to release all available
olanzapine. Olanzapine active ingredient standard was used
to calibrate the system, and dissolution was repeated a
minimum of three times. The Distek dissolution apparatus
was calibrated with three standards for each of the 12
probes (two dissolution baths with six vessels each) and a
standard absorbance curve was calculated for each probe. If
the relative standard deviation was too high, the probe was
not used. Care was taken to randomize the analysis within
the vessels available and thus provide assurance of
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comparable results of tests performed in triplicate on each
generic tablet. Initial disintegration was quick and difficult
to differentiate among some products, so the time to first
measurable concentration of active ingredient in the dis-
solution media (simulated saliva) was used as a proxy,
since the onset of dissolution is normally preceded by
disintegration.
3 Results
3.1 Disintegration Times (Time Taken to Reach Full
Dispersion)
We found that the method of ODT manufacture (see
Table 1 for manufacturing details for all compounds tes-
ted) had the greatest influence on the time for disintegra-
tion; in general, the fastest were freeze dried tablets, then
soft compressed tablets and then hard/dense tablets.
Olanzapine Zydis was the only ODT that completely
disintegrated in less than 4 s for all strengths (5, 10, 15, and
20 mg; Table 4). The second fastest disintegration time
was Prolanz FAST (5/10 mg; 12 s), followed by risperi-
done (4 mg; 40 s).
In the agitated aqueous media of the dissolution vessel
(rather than the sedentary environment of the Petri dish just
described), both olanzapine Zydis and risperidone ODT
disintegrated immediately upon coming into contact with
aqueous media; however, the active compound (olanza-
pine) in the Zydis tablets dissolved faster in the simulated
saliva media (pH 6.8) than the risperidone in the risperi-
done ODTs. Surprisingly, risperidone 2-mg ODT disinte-
grated slower than the 4-mg with double the mass, and was
potentially influenced by the shape and density of the
tablet. Other products varied in their disintegration char-
acteristics, but essentially remained as a clump that did not
always fully disperse when physically agitated after 3 min
of standing without mixing. Compressed tablets consis-
tently had a higher amount of visible residue at the end of
the 3-min evaluation period.
3.1.1 Dissolution Times (Release of Active Product)
Using time to dissolution as a proxy for disintegration,
several generics required 20 s or more to initiate release of
the drug substance (Table 5) and required both increasing
the agitation rate, and additional time (*30 min) to max-
imize dissolution. In this evaluation, only four of the drug
products tested released more than 80 % of the active
ingredient within the first 10 min. Release for all but Zo-
lrix was around 90 % or above after applying 150 rpm for
10 min at the end of the analysis.
3.1.2 5-mg Olanzapine and 4-mg Risperidone ODTs
Figures 1 and 2 are a summary of the 5-mg data at 30-rpm
paddle speed for the first 3 min and first 30 min, respec-
tively. When examining the first 3 min (Fig. 1) of the
dissolution profile, the olanzapine Zydis formulation is
the first to release active compound, with dissolution over
30 % in less than 60 s, twice as fast as the 4-mg risperidone
ODT. The Prolanz FAST 5-mg formulation is also rapid
and after 1 min had higher, although more variable, release
(Fig. 1). Three samples (olanzapine Zydis, Prolanz
FAST, and Novo-Olanzapine OD) were run again at the
lower agitation speed to explore potential differences
between the products; at 20 rpm, only olanzapine Zydis
disintegrated instantly, and Prolanz FAST had a notice-
able delay in the low-agitation environment. Novo-Olan-
zapine OD, a molded tablet, also had a faster dissolution
profile than the remainder of the samples (Fig. 1).
Table 2 Simulated saliva formulation
Ingredient Grams/liter of
purified water
Sodium chloride (NaCl) 0.126
Potassium chloride (KCl) 0.964
Potassium thiocyanide (KSCN) 0.189
Potassium phosphate monobasic (KH2PO4) 0.655
Urea 0.200
Sodium sulfate (Na2SO4 10H2O) 0.763
Ammonium chloride (NH4Cl) 0.178
Calcium chloride dihydrate (CaCl2 2H2O) 0.228
Sodium bicarbonate (NaHCO3) 0.631
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As shown in Fig. 1, olanzapine Zydis is the first to
initiate disintegration and shows a steady rate of dissolu-
tion, whereas some of the generic ODTs were well below
100 % even at the 30-min dissolution time point (Fig. 2).
3.1.3 10-mg Tablets
The Prolanz FAST formulation has a quick dissolution
time, but shows a longer delay to catch up to the Zydis
formulation, taking 2 min before they are equivalent (data
not shown; see Figs. 1, 2 for 5-mg dose profiles). At a
lower agitation rate of 20 rpm, olanzapine Zydis 10 mg
still has the fastest dissolution rate in the first 3 min, and
olanzapine Zydis dissolution is not significantly affected
by dosage strengths (5, 10 mg). However, the Prolanz
FAST dissolution rate is affected by the increased mass of
the tablet.
3.1.4 15-mg Tablets
At 20 min, the generic ODTs released less than 60 % of
active compound, while olanzapine Zydis released 95 %.
At the 90-min time point, and with increased agitation, the
generic ODTs reached 96–112 % release.
3.1.5 20-mg Tablets
The olanzapine Zydis ODT formulation is the fastest to
disintegrate and dissolve. With a longer dissolution time
(90 min) and increased agitation, all products were close to





10 mg; Zapinex FT
5, 10 mg
Lactose monohydrate, hydroxypropyl cellulose, crospovidone,
magnesium stearate, glycerin diacetate, colloidal silicon
dioxide, microcrystalline cellulose, polyethylene glycol 8000,
mint powder
Yellow and red, compressed tablet, stops swelling
in media after 55–75 s, disintegration [180 sa
Anzapine ORO 10 mg Lactose monohydrate, hydroxypropyl cellulose, sodium
cyclamate, magnesium stearate, talc
Compressed tablet, stops swelling in media after
85 s, coarse disintegration [180 sa
CO Olanzapine ODT
15 mg
Not available Pale yellow, round, compressed tablet,
disintegration [180 sa
Lanzaprex 10 mg Lactose, crospovidone, hydroxypropyl cellulose, aerosil, talc,
magnesium stearate, mint aroma
Compressed tablet, stops swelling in media after
44 s, disintegration complete at \180 sb
Novo-Olanzapine OD
5, 15, 20 mg
Mannitol, sodium starch glycolate, dextrose, flavoring,
(tartrazine), FD&C yellow #5 aluminum lake
Yellow (5), pink (15), and blue (20), round,
compression molded tablet fully wetted in 5 s,
disintegrated in \180 sb
Olaxinn 5, 20 mg Crospovidone, lactose monohydrate, colloidal silicon dioxide,
hydroxypropyl cellulose, talc, magnesium stearate, mint
powder
Yellow, round, compressed tablet fully wetted in
5–9 s, disintegrated in \180 sb
pms-Olanzapine ODT
15, 5 mg
Aspartame, colloidal silicon dioxide, crospovidone, guar gum,
magnesium stearate, mannitol, microcrystalline cellulose,
pregelatinized starch, sodium lauryl sulfate
Yellow, round, compressed tablet fully wetted in
5 s, disintegrated in \180 sb
Prolanz FAST 5,
10 mg
Lactose monohydrate, hyprolose, crospovidone,
microcrystalline cellulose, magnesium stearate
Red, 5/10-mg, compressed tablet, disintegrated in
7–12 s, coarse dispersion at 180 s
Sandoz Olanzapine
ODT 20 mg
Colloidal silicon dioxide, crospovidone, flavoring, mint
powder, hydroxypropyl cellulose, lactose monohydrate,
magnesium stearate, talc
Compressed tablet, stops swelling in media after
85 s, disintegrated at 180 s
Zolrix 20 mg Mannitol, microcrystalline cellulose, crospovidone,
hydroxypropyl cellulose, aspartame, calcium silicate,
magnesium stearate
Compressed tablet, disintegrated in media after
25 s, coarse dispersion at 180 s
Zyprexa Zydis 5, 10,
15, 20 mg
Mannitol, aspartame, gelatin, preservatives Fully dispersed in 4 s
Risperdal M-Tab 2,
4 mg
Colloidal silicone dioxide, hypromellose, lactose, magnesium
stearate, microcrystalline cellulose, propylene glycol, sodium
lauryl sulfate, corn starch, colorant
Red, 4-mg, round wafer, fully wetted at 3 s,
disintegrated in 40 s, 2-mg pillow is slower and
lumps
ODT orodispersible tablet
a Disintegration was not complete at 180 s. When the Petri dish was stirred, there was clearly core material still intact
b Disintegration was a slow erosion of the core tablet, and it was not obvious when disintegration was complete; yet when stirred at the end of
180 s, there was no evidence of tablet core material (lump). In these cases, the tablet was said to have disintegrated in\180 s, but significantly
more slowly than Zydis or risperidone (minutes instead of seconds)
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Table 5 Time to first measurable concentration at 30 rpm
Product name Time, percentage released (s, %) by formulation strength
5 mg 10 mg 15 mg 20 mg
ABL Olanzapine FT 0, 1 10, 1 a40 – –
Anzapine ORO – 30, 1 – –
ARIS Olaxinn 0, 1 a5 – – 20, 1
CO Olanzapine ODT – – 20, 2 a25 –
Lanzaprex – 15, 1 a35 – –
Novo-Olanzapine OD 10, 3 a15 – – 30, 1
pms-Olanzapine ODT 10, 2 a15 – 20, 1 –
Prolanz FAST 20, 8 10, 2 a25 – –
Sandoz Olanzapine ODT 20, 1 a25 – – 20, 1 a25
Tanssel D – 30, 1 a35 – –
Zolrix 0, 1 a5 – – 20, 1 a25
Zydis 0, 4 a5 5, 7 0, 1 a5 0, 1
Risperdal M-Tabb 10, 2 – – –
ODT orodispersible tablet
a Unadjusted time as per graph. Some graphs did not start at zero
b Data shown are for the 4-mg dose
Fig. 1 Summary of 5-mg
dissolution data at 30 rpm, up to
3 min. ODT orodispersible
tablet
Fig. 2 Summary of 5-mg
dissolution data at 30 rpm, up to
30 min. ODT orodispersible
tablet
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100 % released at the final time point. The freeze dried
ODT dissolution profiles are very similar regardless of the
tablet mass or active ingredient content. Generic ODT
formulations using conventional compression or molding
methods of manufacture were significantly slower to dis-
solve as the mass of the tablet increased.
4 Discussion
Based on our results, we found potentially important dif-
ferences between ODT formulations manufactured with
different technologies. The simulated saliva in vitro dis-
solution test may be considered a proxy for the disinte-
gration process in a patient’s mouth because it mimics the
oral cavity environment and solutions. Differences in ODT
formulation, manufacturing process, and tablet mass are
associated with different disintegration times, which may
have a potential impact on their use in clinical practice.
Different disintegration times and tablet residue could
influence mouth feel and the ability to swallow unaided by
fluids, which could, in turn, influence adherence to
treatment.
It is important to note that several generic tablet disin-
tegration rates are slow enough to permit ‘cheeking’ and
expectoration of the medication. Surreptitious rejection of
medication by patients occurs sometimes in clinical prac-
tice [15]. If a tablet is swallowed and the pH becomes more
acidic, the olanzapine will dissolve more rapidly than in the
more neutral pH of saliva; however, the time for complete
disintegration may be no better than in the mouth. Clini-
cians need to be aware of the potential differences among
products, because it could differentially influence the suc-
cess of this behavior. The use of polymeric excipients,
which swell in water to speed disintegration, may inhibit
rapid and complete dissolution of the active ingredient in
some formulations.
There are three possible explanations for the low final
dissolution values (\90 %) after 30 min in the dissolution
bath: (1) olanzapine is not very soluble in aqueous solu-
tions close to pH 7, and in these formulations, active
pharmaceutical ingredient particle size may make a dif-
ference; (2) the drug is trapped or bound to excipients; or
(3) analytical interference from the excipients. At 20 min,
generics released less than 60 %, while olanzapine Zydis
released 95 %. With the longer time point (90 min), they
reached 96–112 % release. Generic ODT formulations
using loosely compressed tablets had relatively fast and/or
coarse disintegration but slow dissolution. Olanzapine
Zydis (a freeze dried tablet) was the fastest disintegrating
ODT formulation and exhibited the most effective disso-
lution curve of all the tablet strengths tested, regardless of
potency. The investigated generic olanzapine ODT
products required more than 30 s to dissolve even 10 % of
the active ingredient when compared with olanzapine Zy-
dis ODT, which could release approximately 25 % in the
same time period.
Generic ODT products use different manufacturing
platforms: direct compression; molded tablets; uncoated
tablets; and some with pigment colorants. Risperdal
M-Tab and olanzapine Zydis tablets may have similar
disintegration rates, but the Zydis ODT dissolved at twice
the speed (likely due to the differences in active ingredient
solubility in artificial saliva). In our tests, the smaller mass
of the 5-mg olanzapine ODTs may facilitate the observed
shorter disintegration and dissolution times versus the lar-
ger 20-mg tablets. Generic olanzapine ODT formulations
incorporate water expansive polymers that appeared in the
dispersion as a coarse insoluble residue, which may explain
slow dissolution rates. After 5 min, some generic forms of
olanzapine ODT almost match the dissolution rate of Zy-
dis but do not realize 100 % release.
There are some limitations of our experiments. The
in vitro disintegration times may not be identical to in vivo
disintegration times, and the small number of generic drug
tablets available to the investigation did not permit statis-
tical analysis.
5 Conclusions
The in vitro artificial saliva disintegration and dissolution
tests are a proxy for the disintegration process in a patient’s
mouth. Tablet orodispersibles are consistently slower to
disintegrate and release drug substance than lyophilized
wafers. Compared with olanzapine Zydis ODT, generic
olanzapine ODT formulations of soft compressed tablets
incorporate water expansive polymers that appeared in the
dispersion as a coarse insoluble residue, which may explain
their slow dissolution rates. Furthermore, in a direct com-
parison between risperidone ODT and olanzapine Zydis,
orodispersible drugs with similar manufacturing methods
(lyophilization), it is evident that, even though disintegra-
tion rates are similar, the risperidone is not as soluble in
artificial saliva as is olanzapine. By using these test
methods, differences in the formulation and manufacturing
process of ODTs were seen to have a strong influence on
the disintegration and dissolution of the drug products;
differences that may potentially affect their use in clinical
practice.
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